BB Biotech AG

BB Biotech AG

62.91
USD
-1.45
(-2.26%)
21.96EPS
2.90P/E
3.51BMarket Cap
Jan 22Next Earn

Total Valuation

USD

As of September 30, 2026, BB Biotech AG carries a market capitalization of 3.51B, placing it among publicly traded companies globally. Its enterprise value stands at 3.31B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.51B
Enterprise Value3.31B

Important Dates

BB Biotech AG's next confirmed earnings release is scheduled for January 22, 2027.

Earnings Date1/22/2027

Share Statistics

As of September 30, 2026, BB Biotech AG has 55.15M shares outstanding.

Shares Outstanding55.15M

Valuation Ratios

As of September 30, 2026, BB Biotech AG trades at a trailing price-to-earnings ratio of 2.90. The price-to-sales ratio is 2.82, and the price-to-book ratio stands at 0.90.

PE Ratio2.90
PS Ratio2.82
PB Ratio0.90
P/TBV Ratio0.90

Enterprise Valuation

These figures are as of September 30, 2026. The EV/Sales ratio of 2.50 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 3.31B versus a market cap of 3.51B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales2.50

Financial Efficiency

USD

Over the twelve months ended September 30, 2026, BB Biotech AG posted a return on equity (ROE) of 42.20, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 41.87, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 42.20, useful for judging operating efficiency across full business cycles. The company generates approximately 18.15M in revenue per employee across its workforce of 73.00, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)42.20
Return on Assets (ROA)41.87
Return on Capital Employed (ROCE)42.20
Revenue Per Employee18.15M
Employee Count73.00

Taxes

USD

Over the twelve months ended September 30, 2026, BB Biotech AG recorded 85,102.30 in income tax expense. That works out to an effective tax rate of 0.01, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items. Taxes are levied on pretax income of 1.29B, leaving 1.29B in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.

Income Tax85,102.30
Effective Tax Rate0.01

Stock Price Statistics

USD

As of the close on November 2, 2026, BB Biotech AG's stock has gained approximately 66.46% over the past 52 weeks. The 50-day moving average sits at 74.39, while the 200-day moving average is 74.03.

52-Week Price Change66.46%
50-Day Moving Average74.39
200-Day Moving Average74.03

Income Statement

USD

Over the twelve months ended September 30, 2026, BB Biotech AG generated 1.32B in revenue and converted that into 1.29B in net income, yielding earnings per share of 21.96.

Revenue1.32B
Pretax Income1.29B
Net Income1.29B
Earnings Per Share (EPS)21.96

Balance Sheet

USD

These figures are as of September 30, 2026.

Cash & Cash Equivalents201.17M
Net Debt-201.17M
Equity (Book Value)3.91B
Book Value Per Share70.84

Margins

These figures cover the twelve months ended September 30, 2026.

Pretax Margin97.41
Profit Margin97.40

Dividends & Yields

USD

Over the twelve months ended September 30, 2026, BB Biotech AG paid dividends of 2.53 per share. The dividend payout ratio of 11.53 indicates the proportion of earnings distributed to shareholders, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 4.24, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to BB Biotech AG shareholders.

Dividend Per Share2.53
Payout Ratio11.53
Shareholder Yield4.24

Stock Splits

BB Biotech AG's most recent stock split took place on March 29, 2016 with a 1:5 split ratio.

Last Split Date3/29/2016
Split Ratio1:5